Results 311 to 320 of about 170,525 (342)

Treatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease. [PDF]

J Clin Med
Patel P.
europepmc   +1 more source

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial (SYNCHRONIZE™‐1)

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Survodutide, a novel glucagon receptor and glucagon‐like peptide‐1 (GLP‐1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report
Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Multi-omics analysis elucidates the therapeutic mechanisms of the Quzhi formula in metabolic dysfunction-associated steatohepatitis targeting gut microbiota, lipid metabolism, and the role of its metabolite fraxin. [PDF]

Front Pharmacol
Wu JX, Wu YL, Li MF, Liu N, Liu Y, Huang YP, Gan Y, Wang XY, Chai HS, Xu J, Xi Q, Guo XR, Sheng HM, Shen TT, Zhang Q.   +14 more
europepmc   +1 more source

Effect of Huatan Qushi Huoxue prescription on the key proteins of the ADPN/PI3K/Akt signaling pathway in rats with nonalcoholic steatohepatitis

, 2020
ZHANG Lihui
openalex   +1 more source

Efficacy and safety of European Medicines Agency (EMA)‐approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta‐analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims We aimed at comparing different approved strategies (obesity management medications—OMM, endoscopic bariatric procedures—EBP, and metabolic bariatric surgery—MBS) with lifestyle intervention/placebo/no therapy (LSI/Pbo/NT) for the treatment of different BMI‐based classes of obesity (i.e., overweight—BMI: 25–29.9 kg/m2; class I—BMI: 30–34 ...
Rocco Barazzoni, Matteo Monami, Silvio Buscemi, Luca Busetto, Maurizio De Luca, Giuseppe Navarra, Benedetta Ragghianti, Giovanni Antonio Silverii, Amanda Belluzzi, Edoardo Mannucci, Paolo Sbraccia   +10 more
wiley   +1 more source

HBV reactivation and its metabolomic profile after liver transplantation for hepatocellular carcinoma in non-alcoholic steatohepatitis. [PDF]

Chin J Cancer Res
Chen J, Chen L, Li H, Hu Z, Zhuo J, Chen X, Zhao R, He C, Wu X, Lin Z, Sun J, Wang R, Wei X, Zheng S, Xu X, Lu D.   +15 more
europepmc   +1 more source

Dual GIP/GLP1-RA, GCGR/GLP-1 RA and GLP1-RA for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease with Type 2 Diabetes: A Systematic Review and Meta-analysis. [PDF]

touchREV Endocrinol
Gunawan B, Nugroho H, Sibarani RP.
europepmc   +1 more source

Identification of MEOX1 as a potential target in metabolic dysfunction-associated steatohepatitis-related liver fibrosis

Xinyue Jiao, Linying Lai, Yiting Qian, Bo Sun, Wenzhuo Yang   +4 more
openalex   +1 more source

Medical events and costs associated with metabolic bariatric surgery among adults with type 2 diabetes: A retrospective, matched cohort study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study examined rates of metabolic/bariatric surgery (MBS) among adults with type 2 diabetes and obesity (T2D + O). The study also compared glucose‐lowering medication (GLM) use, costs, comorbidities and medical events for individuals with T2D + O who underwent MBS (cases) to those who did not have MBS (controls).
Kristina S. Boye, Lisa M. Neff, Magaly Perez‐Nieves, Maureen J. Lage, K. Karthik Chivukula   +4 more
wiley   +1 more source

Impact of metabolic endoscopy on fibrosis regression in steatotic liver disease. [PDF]

World J Hepatol
Sierra L, Chatterjee A, Prado R, Khurana A, Patel R, Firkins S, Simons-Linares R.   +6 more
europepmc   +1 more source